Therefore, on the one hand a possible resistance to beneficial FGF-21-mediated effects in states of metabolic disorders, such as obesity or T2D, and on the other hand a reactive increase to overcome the increased energy income and triglyceride (TG) accumulation is discussed (reviewed in [31]). The gene discussed is FGF21; the disease is type 2 diabetes mellitus.